Dr. Agarwal's Health Care H1 FY27 Profit Jumps 50% as Revenue Rises 29% and Eye-Care Network Expands

Dr. Agarwal's Health Care H1 FY27 Profit Jumps 50% as Revenue Rises 29% and Eye-Care Network Expands

Chennai, November 12, 2026: Dr. Agarwal's Health Care Limited reported strong revenue and profit growth for the first half of FY2026–27, supported by higher patient volumes, increasing surgical procedures and the expansion of its specialised eye-care network.

The Chennai-headquartered healthcare company reported consolidated revenue from operations of ₹1,269 crore for the six months ended September 30, 2026, representing year-on-year growth of 28.7%.

Consolidated profit after tax increased 50.1% to ₹112 crore, compared with approximately ₹75 crore in the corresponding period of the previous financial year.

The company also reported EBITDA of ₹362 crore, an increase of 27%, while maintaining an EBITDA margin of approximately 28.2%.

The financial results, announced on November 5, highlight the company's expanding presence in India's organised ophthalmology services market.

Dr. Agarwal's Health Care added 39 facilities during the first half, increasing its network to 324 centres across India and Africa.

The company also reported growth in surgeries and patient visits, indicating that expansion was accompanied by stronger utilisation of its existing healthcare facilities.

For investors, the results place attention on the sustainability of revenue growth, profitability at mature centres, expansion costs and the company's ability to generate returns from new facilities.

Dr. Agarwal's Health Care H1 FY27 Financial Highlights

The results demonstrate that revenue and earnings increased while the company continued investing in network expansion.

Profit growth exceeded revenue growth, resulting in an improvement in the reported net profit margin.

However, EBITDA margins remained broadly stable, indicating that expansion-related costs continued to influence operating profitability.

Revenue Increases 28.7% to ₹1,269 Crore

Dr. Agarwal's Health Care reported consolidated revenue from operations of ₹1,269 crore during H1 FY27.

This compared with ₹986 crore in the corresponding six-month period of FY26.

The increase represented growth of 28.7%.

The performance was supported by rising patient volumes, stronger surgical activity and contributions from the company's expanding network.

Revenue from Indian operations reached ₹1,138 crore, representing year-on-year growth of approximately 28.5%.

India remained the company's principal market, accounting for most of its consolidated revenue.

The company's international operations contributed the remaining revenue, reflecting its presence in African healthcare markets.

For investors, the strong domestic performance demonstrates the importance of India's growing demand for specialised eye-care services.

Net Profit Rises 50.1% to ₹112 Crore

Consolidated profit after tax increased to ₹112 crore in the first half of FY27.

This compared with approximately ₹75 crore in the corresponding period of the previous financial year.

The increase represented growth of 50.1%.

The company's PAT margin improved to 8.7% from 7.4%.

The expansion of approximately 130 basis points indicates that net earnings increased faster than revenue.

Higher patient volumes and revenue from established facilities supported the overall financial performance.

However, profitability must also be evaluated against the costs associated with opening and operating new centres.

New healthcare facilities typically require investment in medical equipment, staff and infrastructure before reaching mature operating volumes.

The company's ability to balance expansion with profitability will remain important during the remainder of FY27.

EBITDA Reaches ₹362 Crore

Dr. Agarwal's Health Care reported EBITDA of ₹362 crore during H1 FY27.

This compared with ₹285 crore a year earlier.

The increase represented growth of approximately 27%.

The EBITDA margin stood at 28.2%, compared with 28.3% in the previous year's first half.

The relatively stable margin indicates that the company maintained operating profitability while expanding its network.

However, new facilities can create initial costs before generating sufficient patient volumes.

These expenses may temporarily affect operating margins.

As facilities mature, improved utilisation can support revenue and operating efficiency.

For investors, the performance of newly opened centres will be an important factor in assessing future margin trends.

September-Quarter Revenue Rises 31.4%

The company also reported strong financial results for the quarter ended September 30, 2026.

Consolidated revenue from operations increased 31.4% year-on-year to ₹655 crore.

This compared with approximately ₹499 crore in Q2 FY26.

Total income reached ₹665 crore, representing growth of 31.3%.

Revenue from Indian operations increased to ₹586 crore, up 31.6% year-on-year.

The September quarter also represented the company's highest quarterly revenue reported up to that point.

The performance demonstrates continued demand for specialised ophthalmology services.

However, quarterly growth includes the contribution of new and acquired facilities alongside revenue generated by existing centres.

Investors will therefore monitor same-store sales growth to assess the underlying performance of established operations.

Q2 FY27 Profit Increases 55.8%

Dr. Agarwal's Health Care reported consolidated profit after tax of approximately ₹57 crore during Q2 FY27.

This compared with approximately ₹36 crore in the corresponding quarter of the previous financial year.

The increase represented growth of 55.8%.

Quarterly EBITDA increased 28.8% to ₹186 crore.

The EBITDA margin stood at approximately 27.9%.

The quarterly PAT margin improved to 8.5% from 7.2%.

The increase in net profitability demonstrates stronger earnings during the reporting period.

However, the EBITDA margin was slightly lower than the year-earlier level.

The distinction suggests that investors should evaluate both operating margins and net profit when assessing financial performance.

Same-Store Sales Growth Reaches 17.7%

One of the most important indicators in the company's results was the performance of its established healthcare facilities.

Dr. Agarwal's Health Care reported same-store sales growth of 17.7% during H1 FY27.

For the September quarter, same-store sales growth reached 18.8%.

The company calculates this measure using facilities established or acquired up to the first half of FY24.

Same-store sales growth measures revenue growth from a comparable group of existing facilities.

It helps distinguish growth generated by established operations from growth resulting from new centre additions.

The strong performance indicates that mature facilities continued increasing revenue.

This is important because new hospitals and clinics typically require time to build patient volumes and achieve operating maturity.

Eye-Care Network Expands to 324 Facilities

Dr. Agarwal's Health Care continued expanding its healthcare network during the first half of FY27.

The company added 39 facilities during the six-month period.

The additions included three tertiary, 31 secondary and five primary facilities.

By September 30, 2026, the company's network had reached 324 facilities.

Of these, 305 were located in India and 19 in Africa.

The Indian network extended across 14 states and five union territories, covering 172 cities.

The expansion strengthens the company's presence across different levels of ophthalmology care.

However, the financial performance of newly opened centres will depend on patient demand, clinical staffing and utilisation.

Company Adds 21 Centres During September Quarter

The September quarter was particularly important for the company's expansion programme.

Dr. Agarwal's Health Care added 21 facilities during Q2 FY27.

These included one tertiary centre, 17 secondary facilities and three primary centres.

Of the 21 additions, 19 were greenfield facilities and two were acquired facilities in Delhi-NCR.

Greenfield facilities are newly established operations rather than existing centres purchased from another operator.

The expansion included facilities across Uttar Pradesh, Andhra Pradesh, Tamil Nadu, Delhi, Maharashtra and several other states.

The company's strategy combines expansion into new markets with a stronger presence in existing regions.

However, new facilities require investment before reaching mature patient volumes.

Investors will assess how quickly these centres contribute to revenue and profitability.

Surgical Procedures Increase 18.8%

Dr. Agarwal's Health Care performed 186,923 surgeries during the first half of FY27.

This represented year-on-year growth of 18.8%.

During the September quarter alone, the company performed 95,841 surgeries.

Quarterly surgical volumes increased 22.2% compared with the corresponding period of FY26.

The increase demonstrates stronger demand for ophthalmology procedures across the network.

Surgical services are an important component of the company's revenue.

However, the financial contribution of each procedure varies depending on the type of surgery, treatment complexity and pricing.

Higher surgical volumes can support revenue growth and improve the utilisation of medical facilities.

The company will need to maintain clinical quality and operational efficiency as volumes increase.

Patient Volumes Rise 28.5%

Dr. Agarwal's Health Care reported serving more than 18.4 lakh patients during the first half of FY27.

The figure represented growth of approximately 28.5%.

The increase reflects stronger demand for consultations, diagnostic services, treatment and surgical care.

Patient volumes are an important operational indicator for specialised healthcare providers.

Higher footfall can support revenue from consultations, diagnostic investigations and subsequent treatment.

However, patient growth must be assessed alongside the mix of services provided.

A rise in consultations does not necessarily translate into an equivalent increase in surgical revenue.

For Dr. Agarwal's Health Care, the combination of higher patient volumes and surgical activity indicates broad growth across its healthcare operations.

Healthcare Services Generate Most Revenue

Dr. Agarwal's Health Care derives revenue from both healthcare services and product sales.

During H1 FY27, services accounted for approximately 77.9% of revenue from operations under the company's disclosed service-and-product classification.

Products accounted for approximately 22.1%.

Healthcare services include surgeries, consultations, treatments and investigations.

Product sales include optical products, contact lenses, accessories and pharmaceutical products.

The revenue mix demonstrates that medical services remain the company's principal business activity.

However, product sales provide an additional revenue stream associated with patient care.

The combination allows the company to serve patients across diagnosis, treatment and ongoing vision-related requirements.

Cataract Surgery Remains an Important Business

Cataract surgery is a major part of ophthalmology services.

A cataract occurs when the natural lens of the eye becomes cloudy, affecting vision.

Surgery involves removing the affected lens and generally replacing it with an artificial intraocular lens.

Demand for cataract treatment is influenced by population ageing, access to healthcare and patient awareness.

Specialised eye-care providers offer different surgical techniques and lens options depending on clinical requirements.

Dr. Agarwal's Health Care reported that advanced procedures represented approximately 30% of cataract surgery volumes.

This indicates patient demand for higher-end treatment options.

However, treatment decisions depend on individual clinical needs and should not be interpreted solely through revenue considerations.

Advanced Eye-Care Procedures Support Service Development

Dr. Agarwal's Health Care continues investing in specialised ophthalmology procedures and medical technology.

The company announced the opening of a dedicated Pinhole Pupilloplasty centre at its Chennai flagship facility.

Pinhole Pupilloplasty is a specialised surgical technique involving the pupil.

The company has indicated plans to extend the procedure across its wider network.

The initiative reflects its focus on developing specialised clinical capabilities.

However, the adoption of new procedures depends on clinical suitability, trained specialists and patient requirements.

The financial contribution of such services cannot be assumed without supporting revenue information.

For investors, medical innovation represents a potential source of service differentiation rather than a guaranteed driver of earnings.

Expansion Costs Remain an Important Consideration

The company's rapid network expansion creates both growth opportunities and financial obligations.

New healthcare facilities require spending on medical equipment, premises, technology and staffing.

They may also incur operating expenses before reaching mature patient volumes.

Dr. Agarwal's Health Care reported that 51 surgical facilities had been launched over the preceding 12 months.

Management indicated that start-up losses associated with new facilities affected the operating environment.

Despite these costs, the company maintained broadly stable EBITDA margins during the first half.

The performance suggests that growth from established operations helped support profitability while the network expanded.

However, future margins will depend on how quickly newer centres reach sustainable utilisation levels.

Healthcare Staffing Supports Network Expansion

Specialised eye-care services require trained ophthalmologists, clinical personnel and supporting staff.

Dr. Agarwal's Health Care reported a medical team comprising more than 1,100 doctors.

The company's expansion programme increases the importance of recruiting and retaining qualified healthcare professionals.

Clinical staffing influences service capacity, patient experience and the availability of specialised procedures.

New facilities must also maintain appropriate equipment and operational systems.

The availability of skilled professionals can affect how quickly new centres become fully operational.

For healthcare investors, staffing capacity and clinical quality are important considerations alongside financial performance.

India's Organised Eye-Care Market Offers Growth Opportunities

India's eye-care market includes independent clinics, hospitals, charitable institutions and organised healthcare chains.

Specialised providers offer consultations, diagnostics, surgeries and related products.

Demand is influenced by population size, ageing, lifestyle-related conditions and access to medical services.

Greater awareness of eye health can encourage patients to seek diagnosis and treatment.

Organised healthcare chains may benefit from established clinical systems, recognised brands and the ability to invest in specialised equipment.

However, expansion opportunities vary across regions.

Affordability, local competition and the availability of medical professionals influence market development.

Dr. Agarwal's Health Care's network expansion reflects its strategy of increasing access to specialised ophthalmology services.

International Operations Add Geographic Diversification

Dr. Agarwal's Health Care operates 19 facilities across Africa.

These centres provide geographic diversification beyond its Indian operations.

International healthcare businesses may face different regulatory, economic and operational conditions.

Currency movements can also influence consolidated financial results.

However, India remains the company's largest market.

The strong growth in Indian revenue during H1 FY27 demonstrates the importance of domestic operations.

Investors will continue assessing the contribution of international facilities alongside the company's expansion in India.

Investors Focus on Profitability of New Centres

The company's financial performance will increasingly depend on the contribution of recently opened facilities.

New centres typically experience a period of lower utilisation while patient awareness and referral networks develop.

As patient volumes increase, operating efficiency may improve.

However, the time required to reach profitability can vary significantly.

Factors include location, medical staffing, competition, service mix and investment costs.

For Dr. Agarwal's Health Care, the strong same-store sales growth of mature facilities provides an important operating indicator.

Nevertheless, investors will monitor whether newer centres can achieve comparable performance over time.

Shareholders Assess Growth and Valuation

Dr. Agarwal's Health Care is listed on the National Stock Exchange under the symbol AGARWALEYE and on the BSE under code 544350.

Its financial results provide investors with updated information about revenue growth, profitability and operational expansion.

The company's strong earnings performance may support expectations for future growth.

However, healthcare stock valuations also depend on capital expenditure, cash generation and returns on investment.

Rapid network expansion can create financial pressure if new centres take longer than expected to become profitable.

Investors must therefore distinguish between reported revenue growth and the long-term economic returns generated by expansion.

The company's future share-price performance will depend on market conditions and the delivery of its business plans.

Outlook for Dr. Agarwal's Health Care in FY27

Dr. Agarwal's Health Care enters the second half of FY27 following strong revenue and profit growth.

The company has expanded its network to 324 facilities while reporting higher patient volumes and surgical procedures.

Its established facilities continue to deliver strong same-store sales growth.

The performance of new centres will remain a central factor in future profitability.

Management's expansion strategy provides opportunities to reach additional patients and develop specialised clinical services.

However, costs associated with new facilities, staffing and medical equipment will continue to influence operating performance.

Investors will monitor patient volumes, surgical growth, EBITDA margins and the profitability of newly established centres.

The company's ability to maintain clinical quality while expanding its network will also remain important.

Conclusion

Dr. Agarwal's Health Care reported consolidated revenue of ₹1,269 crore for H1 FY27, representing year-on-year growth of 28.7%.

Profit after tax increased 50.1% to ₹112 crore, while EBITDA rose 27% to ₹362 crore.

The company also delivered strong September-quarter results, with revenue increasing 31.4% to ₹655 crore and profit after tax rising 55.8% to ₹57 crore.

Operational growth was supported by higher patient volumes, increased surgical activity and continued expansion of the healthcare network.

The company added 39 facilities during the first half, taking its total network to 324 centres across India and Africa.

Same-store sales growth of 17.7% demonstrated continued expansion at established facilities.

For investors, the results highlight the company's growing presence in organised eye care while placing attention on the profitability of new centres, operating margins and the sustainability of healthcare demand.